Analysts at Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a research report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $32.00 price target on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 122.07% from the company’s current price.
Separately, Guggenheim initiated coverage on Sionna Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $45.00 price objective for the company.
Read Our Latest Research Report on SION
Sionna Therapeutics Price Performance
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Is the S&P 500 Ready to Rally? A $1.8M Bet on SPY Says Yes
- How to Short Nasdaq: An Easy-to-Follow Guide
- Consumer Spending Is Slowing—But These Stocks Will Still Thrive
- What is a support level?
- AppLovin Dominates the Digital Economy Despite Bearish Trends
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
